to reporting medicine therapeutic as in III you, that we programs promising different and areas, We areas. our or on antibodies several revolutionize be also within Regeneron of showcased while last Conference, to XI COPD month's proof-of-concept and including Factor capitalize technological year trials. data JPMorgan multiple transformative oncology, scientific to several advancing At the we Thank robust the breakthroughs. and efforts R&D multiple our to have diverse across the rapidly hope practice from anticipate of obesity, pivotal holds disease Phase potential our pipeline for Len. across opportunities This our Healthcare the potential
Regeneron These growth. address for substantial significant needs to programs unmet opportunities for across long-term positioning Regeneron represent categories large commercial
EYLEA these of to X some reported HD positive dosing retinal occlusion, highlight advancements. the in dosed Starting non-inferior every gains HD. demonstrated care X-milligram EYLEA In Phase compared and within vein me recent study EYLEA regimen with vision weeks. where and we opportunities the III QUASAR Let every X-week of standard pipeline data Bayer December, from
presented recently AMD intervals dosing we're wet weeks. to Additionally, with to XX clinical respectively, and and approximately our best-in-class patients together continue profile. the X-week studies follow-up our XX% PHOTON able PULSAR These of DME, LHD HD's the data from data, throughout maintain long-term support EYLEA in
on track submit remain for the indication this supplementary later We to first BLA quarter. in a
syringe to from in Along plan submission physicians. the also with flexibility a seek the HD's up dosing, convenient We to potential FDA the the to every approval is any syringe. category, to anti-VEGF set intervals broadest the a longest greatest set dosing intervals to therapy, weeks, HD prefilled provide dosing indication dosing for extend potentially include FDA and across approval all maximizing the EYLEA's for April EYLEA flexibility in in XX of X-week prefilled to the
in with Europe as and indicated the exceptional treat immunology and DUPIXENT. in Next, safety November, medicine to only X eosinophilic young Union these European the highlighting approved first esophagitis old, U.S. young DUPIXENT patients as the Dupixent's profile. children was and year further and starting making it in In for
for for the The resubmission a was CSU first therapy FDA supplementary XX, action target accepted of target new potentially the in urticaria it BLA making a date April with by chronic recently decade. spontaneous
improvements remission first symptoms Finally, submitted year, is to biologic indication. this disease for pemphigoid last for another marking late our the achieve DUPIXENT as in bullous significant was supplementary only BLA and
interleukin-XX of ongoing DUPIXENT I from launch want from half and Marion year, of COPD RF remind results COPD, We population by Regeneron. treated and will you anticipate discuss discovered reporting this the of in pivotal another our DUPIXENT. with While the in second significant program potentially distinct over itepekimab, partially opportunity oping in the smokers antibody with former to that
lymboceltimib IgE XXXX. throughout data improving food of reactions key These for This the doses. proof-of-concept trial trial fruit immunoglobulin the plus returning, lives allergic As which commitment data allergic in patients at I highlight shared we E X provide our like patient is in eliminate low conditions, XX% ongoing thereby for to allergy. study, long-term our we our the to also prevent severe first IgE to agents initial severe driver or with both potential and Last of levels would and DUPIXENT the total following and compelling from reversing showed IgE, have from plan patients, enroll to month, continuing reductions updates the allergies. specific initial than treatments greater initial clinical part to
within first demonstrated Libtayo now in reported always later year these At reduction disease a continue high-risk results interim these positive that plan this for new last the a oncology recurrence the We death announced the setting with immunotherapy we adjuvant our first data the to for produce month, present failed, risk adjuvant to a half identified. prespecified for to and in CSCC, population. at year. had best-in-class compared combinations the we is ground. meeting foundation to FDA This becoming even Turning effect. high-risk new provides reinforces a highlighting antibodies belief survival break oncology, to submit which assets. of Merck data not signals show treatment same with data the do that class, disease-free XX% other our same of Last safety Libtayo medical Libtayo or first this set where same the to no analysis in that in This in the KEYTRUDA placebo, XXXX benefit
half results best-in-class expected trials early first activity monotherapy exacerbating randomized meaningful ongoing antibody, being it in trial data confidence combined [indiscernible] melanoma Libtayo the is KEYTRUDA additive this PD-X LAG-X confirm will without metastatic in in This an other second might our versus with of settings. in that safety. in combination for to these with this Data Phase combination first-line the melanoma, year. benefit be increase suggests clinical If our to cancer studied in melanoma, III combination demonstrate monotherapy from when compared
CDX our to Turning bispecifics.
of for pleased duration the at BLA to bispecific to we by similar its best-in-class the by CDX dosing of BCMA with myeloma profile, response recently rates issues. linvoseltamab, bispecific the Linvoseltamab announce multiple are resolution We BCMA CDX potential nearly relapsed/refractory administration the due the or reported that for resubmitted differentiated complete be manufacturing to follow-up. clinical have following third-party double and has
the of emphasizing observed novel of lumoseltimab, of Given late and lines the the in are differentiated we safety earlier approaches. level combination therapy, a including monotherapy profile approach efficacy pursuing lines favorable and therapy strength of data of in limited
CDXX where odronextamab half odronextamab, in we we bispecific are XXXX. pleased best-in-class our we lymphoma FDA has relapsed/refractory demonstrated second and to of announce have expect For potentially an follicular the the efficacy, Hematology In December, BLA resubmitted lead-in in CDX evaluable with previously at x lymphoma. Society that decision we for complete safety follicular OLYMPIA confirmatory portion efficacy initial Odronextamab untreated American from presented meeting, delivered of for trial. of III the the patients responses monotherapy results Phase all XX the also
has of achieved standard in complete the historically approximately responses reminder, a As regimen of plus rituximab setting, chemotherapy in XX% care patients. this
patients are in for efficacy early evaluation which of lines of already over again trial, monotherapy both to therapy, once Based Rituxan XX% highlighted in late we odronextamab compared program chemotherapy Phase differentiated on line plus in and our enrollment. II our first-line has impressive monotherapy X head-to-head OLYMPIA this a exploring odronextamab achieved
Our to The combination their science CDXX are with efficacy progressing. suggests PD-X working with solid adverse also bispecifics We're immune-mediated tumors CDX prioritizing while approach concerns that to costimulatory combination enhance this safety fewer bispecifics. mitigate with may related blockade events. for
these year. updates will on provide innovative this later combinations We
has rapidly potential Center from a a Factor to lower delivered prevention profile improved genetic now advancing offers Genetics to unique We're compared market our risk program. targets option. meet a Moving bleeding potentially may domain employing with X improved that to needs. activity, XXX, to efficacy data anticoagulation blood approach need Offering anticoagulation two-pronged more Regeneron patients care XI of which significant the Regeneron different by Factor and supported XI the effective approach of for catalytic provide antibodies standard options. who a
is viable option risk risk ReGeN-XXXX, bleeding otherwise expected other the currently not a anticoagulants. for would who for domain carry Potentially patients targets with which to On the hand, bleeding. the X of lower it a making candidates be highest available
with expected [ positive than this antibodies advancement Regeneron non-inferior and with robust superior both pixaban, we Phase initial across enoxaparin. patient begin data III These enoxaparin enrolling both knee year, was support numerically thromboebulism better with ] antiserobotic multiple total the reported following programs antibodies XXXX broad this into studies the pivotal of proof-of-concept to indications while and of was year. demonstrating types Late data to venous prevention replacement effects, ReGen-XXXX
Moving expansive we and briefly to early obesity, progressing assets. are where programs clinical an pipeline of preclinical
muscle-sparing to expected is without study year. addition quality tezivogrimab in II is improve loss half COURAGE of to after Our the weight with second Phase discontinuing maintenance data This and loss the fully the evaluate with weight garatizumab of semaglutide. trial and of semaglutide the investigating the of enrolled
pipeline, starting Moving siRNA Genetics medicine to approach. our with Regeneron antibody differentiated our plus
III ASH exploratory our Annual for Phase program to potential from diseases. in at We presented results lateral the hemoglobin updated urea. compelling have an a address multiple Meeting, December, cohort In complement-mediated we paroxysmal
ravulizumab of When the their combination control switched remained only were our LDH also greater disease to became combination, compared ravulizumab current which normal, normal standard lowered our achieved and levels normalized. LDH than range. mean mean higher patients care, combination the to levels, Our to
are also combination generalized We half year. with of this expected gravis in evaluating the results pivotal this second myasthenia in
dry geographic we over we age-related advantages our exploring intravitreal combination addition, approach approved III believe has systemic several program macrodegeneration this in our recently in In agents. atrophy initiated Phase where currently
therapy to ] hearing XX our least data range. with We gene an inner AAV-based out clinical that reaching [ hearing month suffering to later with dual at reported we data the last from and look vector OTO deficit. is ear increase therapy one children children a assessment DB-OTO, profound program, treated normal post-treatment XX of continuing showed enable in genetic year. to program additional forward We hearing notable hearing some the the genetic For autoferilin loss, gene delivered from for ongoing share DB this to announced
this [indiscernible] Regarding with collaboration tau siRNA Alzheimer's programs, new synuclein including year. CNS for and with and initiating advancing diseases are other later , several our trials Parkinson's neurodegenerative we for
recent computational would revolutionize big I approaches be care health the like field to highlight necessary leadership that data will structured the to finally, industry. that extend of allow position in our And X advances to
decade, records. largest have high-throughput enabling individuals, Over encompassing in past world's linked leader DNA DNA create health G&A us sequence the become we health sequencing, million the the care care de-identified database, human X to all with linked to nearly sequence
reflected selection on data in sequence proteomics, U.K. for emerging Biobank generate the the leaders now previous the as our selection are the proteomics building We U.K. the Biobank. the of high-throughput the to proteomics also Regeneron as Center project, for data pharma Genetic by provide to
our strategic Importantly, leading to and additional expected both database network with from dramatically individuals up health is system new to opportunity of proteomics U.S. with generate to Truveta include Truveta's million the our sequence collaboration information. XX expand an to DNA
health While data help it future efforts proven our I health to revolutionize in position and our development we contribute excited more summary, and space industry. of of and big Regeneron about invaluable discovery practice ultimately to care and field analytics leadership have care drug us In been for the revolutionizing can has believe never medicine our this transform already the the the of potential management.
readouts more several throughout and and than is pivotal or exciting ever, we positioning innovative success. XXXX, for long-term pipeline proof-of-concept Our anticipate Regeneron data
over Let me Marion. now to turn the call
